These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 6091709)

  • 21. Procainamide elimination kinetics in pediatric patients.
    Singh S; Gelband H; Mehta AV; Kessler K; Casta A; Pickoff AS
    Clin Pharmacol Ther; 1982 Nov; 32(5):607-11. PubMed ID: 7128001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of N-acetylprocainamide in patients profiled with a stable isotope method.
    Atkinson AJ; Ruo TI; Piergies AA; Breiter HC; Connelly TJ; Sedek GS; Juan D; Hubler GL; Hsieh AM
    Clin Pharmacol Ther; 1989 Aug; 46(2):182-9. PubMed ID: 2474402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The quantitative disposition of procainamide and N-acetylprocainamide in the rat.
    Schneck DW; Grove K; Dewitt FO; Shiroff RA; Hayes AH
    J Pharmacol Exp Ther; 1978 Jan; 204(1):219-25. PubMed ID: 619132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical pharmacokinetics of N-acetylprocainamide.
    Connolly SJ; Kates RE
    Clin Pharmacokinet; 1982; 7(3):206-20. PubMed ID: 6178545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levofloxacin and ciprofloxacin decrease procainamide and N-acetylprocainamide renal clearances.
    Bauer LA; Black DJ; Lill JS; Garrison J; Raisys VA; Hooton TM
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1649-51. PubMed ID: 15793163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure.
    Arimori K; Nakano M
    J Pharmacobiodyn; 1988 Jul; 11(7):504-11. PubMed ID: 2460613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide.
    Klotz U; Arvela P; Rosenkranz B
    Eur J Clin Pharmacol; 1985; 28(6):671-5. PubMed ID: 2866097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of procainamide in chronic ambulatory peritoneal dialysis: report of a case.
    Kroboth PD; Mitchum K; Puschett JB
    Am J Kidney Dis; 1984 Jul; 4(1):78-9. PubMed ID: 6204527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aging and renal clearance of procainamide and acetylprocainamide.
    Reidenberg MM; Camacho M; Kluger J; Drayer DE
    Clin Pharmacol Ther; 1980 Dec; 28(6):732-5. PubMed ID: 6160015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ethanol-induced increase in procainamide acetylation in man.
    Olsen H; Mørland J
    Br J Clin Pharmacol; 1982 Feb; 13(2):203-8. PubMed ID: 7059417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical pharmacokinetics of procainamide.
    Karlsson E
    Clin Pharmacokinet; 1978; 3(2):97-107. PubMed ID: 346289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circadian changes in procainamide and N-acetylprocainamide kinetics in the rat.
    Bruguerolle B; Jadot G
    J Pharm Pharmacol; 1985 Sep; 37(9):654-6. PubMed ID: 2416904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-Acetylprocainamide levels in patients with end-stage renal failure.
    Gibson TP; Matusik EJ; Briggs WA
    Clin Pharmacol Ther; 1976 Feb; 19(2):206-12. PubMed ID: 1261157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal clearance of pyridostigmine in myasthenic patients and volunteers under the influence of ranitidine and pirenzepine.
    Eiermann B; Sommer N; Winne D; Schumm F; Maier U; Breyer-Pfaff U
    Xenobiotica; 1993 Nov; 23(11):1263-75. PubMed ID: 8310710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cimetidine inhibits renal procainamide clearance.
    Christian CD; Meredith CG; Speeg KV
    Clin Pharmacol Ther; 1984 Aug; 36(2):221-7. PubMed ID: 6204803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacokinetics of slow-release procainamide.
    Tilstone WJ; Lawson DH; Campbell W; Hutton I; Lawrie TD
    Eur J Clin Pharmacol; 1978 Dec; 14(4):261-5. PubMed ID: 729620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of ranitidine in patients with renal failure.
    Garg DC; Baltodano N; Jallad NS; Perez G; Oster JR; Eshelman FN; Weidler DJ
    J Clin Pharmacol; 1986 Apr; 26(4):286-91. PubMed ID: 3700684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Procainamide disposition in obesity.
    Christoff PB; Conti DR; Naylor C; Jusko WJ
    Drug Intell Clin Pharm; 1983; 17(7-8):516-22. PubMed ID: 6191939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of ranitidine on the disposition of lignocaine.
    Robson RA; Wing LM; Miners JO; Lillywhite KJ; Birkett DJ
    Br J Clin Pharmacol; 1985 Aug; 20(2):170-3. PubMed ID: 4041336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disposition of procainamide in patients with chronic congestive heart failure receiving medical therapy.
    Tisdale JE; Rudis MI; Padhi ID; Borzak S; Svensson CK; Webb CR; Acciaioli J; Ware JA; Krepostman A; Zarowitz BJ
    J Clin Pharmacol; 1996 Jan; 36(1):35-41. PubMed ID: 8932541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.